港股医药板块走强，港股创新药ETF（159567）早盘涨超1%

Group 1 - The Hong Kong pharmaceutical sector showed a quick recovery after a slight dip, with companies like CSPC Pharmaceutical, 3SBio, Rongchang Biopharmaceutical, and Hengrui Medicine leading the gains [1] - The Hong Kong Innovative Drug ETF (159567) rose by 1.27% as of 9:59 AM, indicating a potential for a three-day winning streak, with a trading volume exceeding 290 million yuan [1] - Since the beginning of this month, the product's shares have increased by 58.7 million, with a cumulative net inflow of over 480 million yuan [1] Group 2 - The current innovative drug market differs from the period of 2019-2021, as the narrative of Chinese innovative drugs going global has transitioned into a phase of actual realization, with transaction amounts reaching new highs [1] - This reflects a leap in China's innovation capability from "quantity" to "quality," supported by continuous domestic policy initiatives that comprehensively back innovative drugs, including the introduction of a commercial insurance directory [1] - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect [1]